Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
CrossRef PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma Jitong Zhou, Meng Gao, Shikun Zhang, WingWa Guo, Wenzhi He, Minghe Zhang, Xi Chen, Cairang Dongzhi, Xiaomian Li, Yufeng Yuan, Weijie Ma Advanced Science .2025;[Epub] CrossRef Pathogenesis and Treatment of Hepatocellular Carcinoma Associated with Nonalcoholic Steatohepatitis Advances in Clinical Medicine .2025
Sublingual delivery can improve absorption for some small peptides, but evidence is limited and quality is unregulated outside approved drugs
General subcutaneous injection sites include the abdomen, outer thigh, and back/side of the upper arm when a clinician has prescribed a subcutaneous medicine
Niraparib showed promising activity in preclinical models and phase I clinical trials, achieving its pharmacodynamic target for PARP inhibition in epithelial ovarian cancer, particularly in patients who have responded to platinum-based chemotherapy 167 (Fig
US$ 26.31
US$ 23.78
US$ 20.73
US$ 24.19
US$ 26.67
US$ 21.13
